Enterprise Value
208.6B
Cash
3.174B
Avg Qtr Burn
-289.4M
Short % of Float
0.23%
Insider Ownership
19.85%
Institutional Own.
48.17%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BRUKINSA (zanubrutinib) Details Chronic lymphocytic leukemia, Blood cancer, Small lymphocytic lymphoma , Cancer | Approved Update | |
BRUKINSA + obinutuzumab Details Cancer, Follicular lymphoma | Approved Quarterly sales | |
TEVIMBRA (tislelizumab) Details Cancer, Esophageal Squamous Cell Carcinoma | Approved Quarterly sales | |
Tislelizumab + chemo Details Cancer, Gastroesophageal adenocarcinomas | PDUFA Approval decision | |
TEVIMBRA (tislelizumab) Details Esophageal Squamous Cell Carcinoma, Cancer | PDUFA Approval decision | |
Ociperlimab (Anti-TIGIT) Details Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
Sonrotoclax / BGB-11417 (Bcl-2 inhibitor) Details Waldenstrom macroglobulinemia | Phase 3 Data readout | |
BRUKINSA + tislelizumab Details Cancer, Hepatocellular carcinoma | Phase 3 Data readout | |
Tislelizumab Details Cancer, Non-small cell lung carcinoma | Phase 3 Data readout | |
Sonrotoclax / BGB-11417 (Bcl-2 inhibitor) + BRUKINSA Details Chronic lymphocytic leukemia | Phase 3 Data readout | |
Ociperlimab (anti-TIGIT Ab) + tislelizumab Details Cervical cancer, Esophageal Squamous Cell Carcinoma, Non-small cell lung carcinoma, Small cell lung cancer | Phase 2 Data readout | |
Sonrotoclax / BGB-11417 (Bcl-2 inhibitor) + Zanubrutinib Details Chronic lymphocytic leukemia | Phase 1/2 Data readout | |
BGB-16673 (BTK CDAC) Details Cancer, B-cell malignancies | Phase 1 Data readout | |
BGB-A445 w/ tislelizumab Details Renal cell carcinoma, Cancer, Bladder cancer, Melanoma | Phase 1 Update |